Asahi Kasei (TYO:3407) subsidiary Zoll Medical announced the launch of and first patient prescription for the Zoll µCor (pronounced “micro core”) heart failure and arrhythmia management system (HFAMS), designed to help clinicians improve outcomes and reduce hospitalizations for heart failure patients with fluid management problems.
Zoll HFAMS is an FDA-cleared, patch-based, wireless system that employs novel radiofrequency technology to monitor pulmonary fluid levels, an early indicator for heart failure decompensation. The HFAMS sensor is non-invasive and can be worn by patients 24 hours a day. The device is designed to continuously record, store, and transmit patient data, including thoracic fluid index, heart rate, respiration rate, activity, posture, and heart rhythm (ECG).